Skip to main content Accessibility help
×
Home
Hostname: page-component-7ccbd9845f-9nx8b Total loading time: 2.841 Render date: 2023-01-29T12:08:55.914Z Has data issue: true Feature Flags: { "useRatesEcommerce": false } hasContentIssue true
Hematopoietic Cell Transplants Hematopoietic Cell Transplants
Concepts, Controversies and Future Directions
Buy print or eBook[Opens in a new window]

Book contents

Section 16 - Novel Transplant Strategies

Published online by Cambridge University Press:  24 May 2017

Hillard M. Lazarus
Affiliation:
Case Western Reserve University, Ohio
Robert Peter Gale
Affiliation:
Imperial College London
Armand Keating
Affiliation:
University of Toronto
Andrea Bacigalupo
Affiliation:
Ospedale San Martino, Genoa
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Kerry Atkinson
Affiliation:
University of Queensland
Syed Ali Abutalib
Affiliation:
Midwestern Regional Medical Center, Cancer Treatment Centers of America, Chicago
Get access
Type
Chapter
Information
Hematopoietic Cell Transplants
Concepts, Controversies and Future Directions
, pp. 559 - 590
Publisher: Cambridge University Press
Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Reisner, Y, Kapoor, N, Kirkpatrick, D, et al. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood. 1983;61(2):341–8.Google ScholarPubMed
Friedrich, W, Hönig, M. HLA-haploidentical donor transplantation in severe combined immunodeficiency. Immunol Allergy Clin North Am. 2010;30(1):3144.CrossRefGoogle ScholarPubMed
Martelli, MF, Aversa, F, Bachar-Lustig, E, et al. Transplants across human leukocyte antigen barriers. Semin Hematol. 2002;39(1):4856.CrossRefGoogle ScholarPubMed
Bachar-Lusting, E, Rachamim, N, Li, HW, et al. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995;1:1268–73.Google Scholar
Rachamin, N, Gan, J, Segall, H, Krauthgamer, R, et al. Tolerance induction by “megadose” hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation. 1998;65:1386–93.Google Scholar
Gur, H, Krauthgamer, R, Berrebi, A, et al. Tolerance induction by megadose hematopoietic progenitor cells: expansion of veto cells by short-term culture of purified human CD34(+) cells. Blood. 2002;99:4174–81.CrossRefGoogle ScholarPubMed
Gur, H, Krauthgamer, R, Bachar-Lustig, E, et al. Immune regulatory activity of CD34+ progenitor cells: evidence for a deletion-based mechanism mediated by TNF-alpha. Blood. 2005;105(6):2585–93.CrossRefGoogle ScholarPubMed
Aversa, F, Tabilio, A, Terenzi, A, et al. Successful engraftment of T-cell-depleted haploidentical “three-loci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994;84:3948–55.Google ScholarPubMed
Aversa, F, Tabilio, A, Velardi, A, et al. Treatment of high risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186–93.CrossRefGoogle ScholarPubMed
Aversa, F, Terenzi, A, Tabilio, A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23(15):3447–54.CrossRefGoogle ScholarPubMed
Aversa, F, Martelli, MF, Velardi, A. Haploidentical hematopoietic stem cell transplantation with a megadose T-cell-depleted graft: harnessing natural and adaptive immunity. Semin Oncol. 2012;39(6):643–52.CrossRefGoogle ScholarPubMed
Ruggeri, L, Capanni, M, Urbani, E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:20972100.CrossRefGoogle ScholarPubMed
Ruggeri, L, Aversa, F, Martelli, MF, Velardi, A. Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev. 2006;214:202–18.CrossRefGoogle ScholarPubMed
Velardi, A, Ruggeri, L, Mancusi, A, Aversa, F, Christiansen, FT. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr Opin Immunol. 2009;21(5):525–30.CrossRefGoogle ScholarPubMed
Ciceri, F, Labopin, M, Aversa, F, et al. Acute Leukemia Working Party (ALWP) of European Blood and Marrow Transplant (EBMT) Group. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 2008;112(9):3574–81.CrossRefGoogle Scholar
Moretta, L, Moretta, A. Killer immunoglobulin-like receptors. Curr Opin Immunol. 2004;16:626–33.CrossRefGoogle ScholarPubMed
Moretta, L, Locatelli, F, Pende, D, Marcenaro, E, Mingari, MC, Moretta, A. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood. 2011;117(3):764–71.CrossRefGoogle ScholarPubMed
Yawata, M, Yawata, N, Draghi, M, Little, AM, Parteniou, F, Parham, P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med. 2006;203:633–45.CrossRefGoogle ScholarPubMed
Leung, W, Iyengar, R, Turner, V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004;172:644–50.CrossRefGoogle ScholarPubMed
Haas, P, Loiseau, P, Tamouza, R, et al. NK-cell education is shaped by donor HLA genotype after unrelated allogeneic hematopoietic stem cell transplantation. Blood. 2011;117(3):1021–9.CrossRefGoogle ScholarPubMed
Perruccio, K, Tosti, A, Burchielli, E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106(13):4397–406.CrossRefGoogle ScholarPubMed
Feuchtinger, T, Opherk, K, Bethge, WA, Topp, MS, Schuster, FR, Weissinger, EM et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116(20):4360–7.CrossRefGoogle ScholarPubMed
Leen, AM, Christin, A, Myers, GD, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein–Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009;114(19):4283–92.CrossRefGoogle Scholar
Comoli, P, Schilham, MW, Basso, S, et al. T-cell lines specific for peptides of adenovirus hexon protein and devoid of alloreactivity against recipient cells can be obtained from HLA-haploidentical donors. J Immunother. 2008;31(6):529–36.CrossRefGoogle ScholarPubMed
Comoli, P, Basso, S, Zecca, M, et al. Preemptive Therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant. 2007;7(6):1648–55.CrossRefGoogle ScholarPubMed
Perruccio, K, Topini, F, Tosti, A, et al. Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation. Blood Cells Mol Dis. 2008; 40(1):7683.CrossRefGoogle ScholarPubMed
Mielke, S, Nunes, R, Rezvani, K, et al. A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood. 2008;111(8):4392–402.CrossRefGoogle Scholar
Roy, DC, Guerin, M, Boumedine, RS, et al. Reduction in incidence of severe infections by transplantation of high doses of haploidentical T cells selectively depleted of alloreactive units. ASH Annual Meeting Abstracts. 2011;118(21):3020.Google Scholar
Marktel, S, Magnani, Z, Ciceri, F, et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood. 2003;101(4):1290–8.CrossRefGoogle ScholarPubMed
Ciceri, F, Bonini, C, Gallo-Stampino, C, Bordignon, C. Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation. Cytotherapy. 2005;7(2):144–9.CrossRefGoogle ScholarPubMed
Ciceri, F, Bonini, C, Stanghellini, MTL, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009; 10(5):489500.CrossRefGoogle ScholarPubMed
Vago, L, Oliveira, G, Bondanza, A. T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation. Blood. 2012;120(9):1820–30.CrossRefGoogle ScholarPubMed
Bader, P, Soerensen, J, Jarisch, A, et al. Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19 depleted stem cells. Best Pract Res Clin Haematol. 2011;24(3):331–7.CrossRefGoogle ScholarPubMed
Bethge, WA, Haegele, M, Faul, C, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells Mol Dis. 2008;40(1):13–9.CrossRefGoogle ScholarPubMed
Chaleff, S, Otto, M, Barfield, RC, et al. A large-scale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy. 2007;9(8):746–54.CrossRefGoogle ScholarPubMed
Handgretinger, R. New approaches to graft engineering for haploidentical bone marrow transplantation. Semin Oncol. 2012;39(6):664–73.CrossRefGoogle ScholarPubMed
Handgretinger, R, Lang, P, Feuchtinger, TF, et al. Transplantation of TcR {alpha}{beta}/CD19 depleted stem cells from haploidentical donors: robust engraftment and rapid immune reconstitution in children with high risk leukemia. ASH Annual Meeting Abstracts. 2011;118:1005.Google Scholar
Carding, SR, Egan, PJ. Gammadelta T cells: functional plasticity and heterogeneity. Nat Rev Immunol. 2002;2(5):336–45.CrossRefGoogle ScholarPubMed
Locatelli, F, Bauquet, A, Palumbo, G, Moretta, F, Bertaina, A. Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation. Immunol Lett 2013;155(1–2):21–3.CrossRefGoogle ScholarPubMed
Bertaina, A, Merli, P, Rutella, S, et al. HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders Blood. 2014;124(5):822–6.CrossRefGoogle Scholar
Prezioso, L, Bonomini, S, Lambertini, C, et al. Haploidentical stem cell transplantation after negative depletion of T cells expressing the αβ chain of the T-cell receptor (TCR) for adults with hematological malignancies. Blood 2013;122:4609 (Abstract).Google Scholar
Aversa, F. Ex vivo TCRα/β/CD19 T and B cell depletion in HSCT for treatment of adult patients with hematological disease. Milteni Symposium on Cellular therapy: Facts, developments, future visions, EBMT meeting, Milan 2014 (Abstract).
Hoffmann, P, Ermann, J, Edinger, M, Fathman, CG, Strober, S. Donor-type CD4+CD25+ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389–99.CrossRefGoogle ScholarPubMed
Nguyen, VH, Shashidhar, S, Chang, DS, et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood. 2008;111(2):945–53.CrossRefGoogle ScholarPubMed
Edinger, M, Hoffmann, P, Ermann, J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144–50.CrossRefGoogle ScholarPubMed
Di Ianni, M, Del Papa, B, Cecchini, D, et al. Immunomagnetic isolation of CD4+CD25+FoxP3+ natural T regulatory lymphocytes for clinical applications. Clin Exp Immunol. 2009;156:246–53.CrossRefGoogle Scholar
Di Ianni, M, Falzetti, F, Carotti, A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117(14):3921–8.CrossRefGoogle ScholarPubMed
Trenado, A, Charlotte, F, Fisson, S, et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest. 2003;112(11):1688–96.CrossRefGoogle ScholarPubMed
Martelli, MF, Di Ianni, M, Ruggeri, L, et al. A. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007;110(1):433–40.Google Scholar
Martelli, MF, Di Ianni, M, Ruggeri, L, et al. “Designed” grafts for HLA-haploidentical stem cell transplantation. Blood 2014;123(7):967–73.CrossRefGoogle ScholarPubMed
Anasetti, C, Beatty, PG, Storb, R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol. 1990;29(2):7991. PubMed PMID: 2249952.CrossRefGoogle ScholarPubMed
Anasetti, C, Amos, D, Beatty, PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320(4):197204. PubMed PMID: 2643045.CrossRefGoogle ScholarPubMed
Beatty, PG, Clift, RA,. Mickelson, EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313(13):765771.CrossRefGoogle ScholarPubMed
Powles, RL, Morgenstern, GR, Kay, HE, et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet. 1983;1(8325):612615.CrossRefGoogle ScholarPubMed
Passweg, JR, Baldomero, H, Gratwohl, A, et al. and for the European Group for Blood and Marrow Transplantation (EBMT). The EBMT activity survey: 1990–2010. Bone Marrow Transplant. 2012;47:906–23.CrossRefGoogle ScholarPubMed
Lu, D-P, Dong, L, Wu, T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107(8):3065–73.CrossRefGoogle ScholarPubMed
Ji, S-Q, Chen, H-R, Yan, H-M, et al. Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies. Bone Marrow Transplant. 2005;36(4):349–54.CrossRefGoogle ScholarPubMed
Di Bartolomeo, P, Santarone, S, De Angelis, G, et al. Unmanipulated bone marrow transplantation from haploidentical related donors for patients with high risk hematologic malignancies. Blood 2010;116:Abstract 2350.Google Scholar
Sanz, J, Boluda, JCH, Martín, C, et al. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplantation. 2012;47(10):1287–93.CrossRefGoogle ScholarPubMed
Noviello, M, Forcina, A, Lupo-Stanghellini, MT, et al. Early reconstitution of T-cell immunity to CMV after HLA-haploidentical hematopoietic stem cell transplantation is a strong surrogate biomarker for lower non-relapse mortality rates. ASH Annual Meeting Abstracts 2012;120:4191Google Scholar
Santos, GW, Owens, AH. Production of graft-versus-host disease in the rat and its treatment with cytotoxic agents. Nature. 1966;210(5032):139–40.CrossRefGoogle ScholarPubMed
Luznik, L, O’Donnell, PV, Symons, HJ, et al. HLA-haploidentical bone marrow ransplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–50.CrossRefGoogle Scholar
McCurdy, SR, Kanakry, JA, Showel, MM, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125(19):3024–31.CrossRefGoogle ScholarPubMed
Raiola, AM, Dominietto, A, Ghiso, A, et al. Unmanipulated haploidentical bone marrow transplant and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013;19;117–22.CrossRefGoogle ScholarPubMed
Castagna, L, Crocchiolo, R, Furst, S, et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2014;20:724–9.CrossRefGoogle ScholarPubMed
Solomon, S, Sizemore, C, Zhang, Z, et al. TBI-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Blood. 2014;124:426(Abstract).Google Scholar
Grosso, D, Gaballa, S, Alpdogan, O, et al. A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease. Biol Blood Marrrow Transplant. 2015;21(4):646–52.CrossRefGoogle ScholarPubMed
Halter, J, Kodera, Y, Urbano-Ispizua, A, et al. for the European Group for Blood and Marrow Transplantation (EBMT) Activity Survey Office. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica. 2009;94:94101.CrossRefGoogle ScholarPubMed
Kanakry, CG, Tsai, HL, Bolan˜os-Meade, J, et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014;124:3817–27.CrossRefGoogle ScholarPubMed
Bradstock, KF, Bilmon, I, Kwan, J, et al. Single-agent high-dose cyclophosphamide for graft-versus-host disease prophylaxis in human leukocyte antigen matched reduced-intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21:934–53.CrossRefGoogle Scholar
Kanakry, CG, O’Donnell, PV, Furlong, T, et al. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014;32(31):3497–505.CrossRefGoogle ScholarPubMed
Holtick, U, Chemnitz, JM, Shimabukuro-Vornhagen, A, et al. OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur J Haematol. 2016;96(1):2735.CrossRefGoogle ScholarPubMed
Bashey, A, Zhang, X, Sizemore, CA., et al. T-cell–replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31:1310–16.CrossRefGoogle ScholarPubMed
Raiola, AM, Dominietto, A, di Grazia, C, et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant. 2014;20:1573–9.CrossRefGoogle ScholarPubMed
Ciurea, SO, Zhang, MJ, Bacigalupo, AA, et al. Haploidentical transplant with post-transplant cyclophosphamide versus matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033–40.CrossRefGoogle Scholar
Kekre, N, Antin, J. Hemopoietic stem cell transplant sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood. 2014;124:334–9.CrossRefGoogle Scholar

References

Broxmeyer, HE, Gordon, GW, Hangoc G, G, et al. Human umbilial cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA 1989;86.10: 3828–32.CrossRefGoogle ScholarPubMed
Gluckman, E, Broxmeyer, HE, Auerbach, AD, et al. Hematopoietic reconstitution in a patient with Fanconi anemia by means of umbilical-cord blood from an HLA-identical sibling. N Eng J Med 1989;321.17: 1174–78.CrossRefGoogle Scholar
Auerbach, AD, Liu, O, Ghosh, R, et al. Prenatal identification of potential donors for umbilical cord blood transplantation for Fanconi anemia. Transfusion 1990;30.8: 682–7.CrossRefGoogle ScholarPubMed
Rubinstein, P, Dobrila, L,Rosenfield, RE, et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA 1995;92: 10119–22.CrossRefGoogle ScholarPubMed
Kurtzberg, J, Laughlin, M, Graham, ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. New Engl J Med 1996;335.3: 157–66.CrossRefGoogle ScholarPubMed
Wagner, JE, Barker, JN, Defor, TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases. Blood 2002;100: 1611–8.Google ScholarPubMed
Rocha, V, Cornish, J, Sievers, E. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2010;97.10: 2962–71.Google ScholarPubMed
Eapen, M, Rubinstein, P, Zhang, MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukemia: a comparison study . Lancet 2007;369.9577: 1947–54.CrossRefGoogle ScholarPubMed
Prasad, VK, Mendizabal, A, Parikh, SH, et al. Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composisiton of the graft on transplantation outcomes. Blood 2008;112.7: 2979–89.CrossRefGoogle ScholarPubMed
Wagner, JE, Eapen, M, Carter, SL, et al. No survival advantage after double vs single cord blood transplantation in children with hematologic malignancy. Blood 2012;120.21: 359a.Google Scholar
Laughlin, MJ, Barker, J, Bambach, B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001;344.24: 1815–22.CrossRefGoogle ScholarPubMed
Ooi, J, Takahashi, S, Tomonari, A, et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with acute myelogeneous leukemia. Biol Blood Marrow Transplant 2008;14.12: 1341–47.Google Scholar
Mori, T, Tanaka, S, Tsukada, N, et al. Prospective multicenter study of single-unit cord blood transplantation with myeloablative conditioning for adult patients with high-risk malignancies. Biol Blood Marrow Transplant 2013;19: 486–91.CrossRefGoogle Scholar
Sanz, J, Boluda, JC, Martin, C, et al. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematologic malignancy using busulfan, thiotepa, fludarabine, and ATG as myeloablative conditioning regimen. Bone Marrow Transplant 2012;47.10: 1287–93.CrossRefGoogle ScholarPubMed
Ballen, KK, Gluckman, E, Broxmeyer, H. Umbilical cord blood transplantation: The first 25 years and beyond. Blood 2013;122.4: 491–8.CrossRefGoogle ScholarPubMed
Barker, JN, Weisdorf, DJ, DeFor, TE, et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced intensity conditioning. Blood 2003;102.5: 1915–19.CrossRefGoogle ScholarPubMed
Ballen, KK, Spitzer, TR, Yeap, BY, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007;13.1: 8289.CrossRefGoogle ScholarPubMed
Cutler, C, Stevenson, K, Kim, HT, et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus based GVHD prophylaxis. Bone Marrow Transplant 2011;46.5: 273–77.CrossRefGoogle ScholarPubMed
Ramirez, P, Wagner, JE, DeFor, TE, et al. Factors predicting single-unit predominance after double umbilical cord blood transplantation. Bone Marrow Transplant 2012;47.6: 799803.CrossRefGoogle ScholarPubMed
Verneris, MR, Brunstein, CG, Barker, J, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009;114.9: 4293–9.CrossRefGoogle ScholarPubMed
Labopin, M, Ruggeri, M, Gorin, NC, et al. Cost-effectiveness and clinical outcomes of double vs single cord blood transplants in adults with acute leukemia in France. Leukemia 2014;99.3: 535–40.Google ScholarPubMed
Barker, JN, Scaradavou, A, Stevens, CE, et al. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood 2010;115.9: 1843–49.CrossRefGoogle ScholarPubMed
Takanashi, M, YAtsuta, K Fujiwara, et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 2010;116.15: 2839–46.CrossRefGoogle ScholarPubMed
Cutler, C C, Kim, HT, Sun, L, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 2011;118.25: 6691–97.CrossRefGoogle ScholarPubMed
van Rood, JJ, Stevens, CE, Smits, J, et al. Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcomes in hematological malignancies. Proc Natl Acad Sci USA 2009;106.47: 19952–7.CrossRefGoogle Scholar
Rocha, V, Spellman, S, Zhang, MJ, et al. Effect of HLA-matching recipients to donor noninherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2012;18.12: 1890–96.CrossRefGoogle ScholarPubMed
Eapen, M, Klein, JP, Sanz, GF, et al. Effect of donor-recipient matching at HLA A, B, C and DRB1 on outcomes after umbilical cord blood transplantation for leukemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol 2011;12.13: 1214–21.CrossRefGoogle ScholarPubMed
Garfall, A, Kim, H, Cutler, C, et al. Allele level matching at HLA-C or DRB1 is associated with improved survival after reduced intensity cord blood transplantation. Blood 2012;120.21: 2010a (Abstract).Google Scholar
Eapen, M, Klein, JP, Ruggeri, A, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood 2014;123.1: 133–40.CrossRefGoogle ScholarPubMed
Garfall, A, Kim, HT,Sun, L, et al. KIR-ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation. Bone Marrow Transplant 2013 ;48.7: 1000–2.CrossRefGoogle Scholar
Brunstein, CG, Wagner, JE, Weisdorf, DJ, et al. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplants depends on transplantation conditioning intensity. Blood 2009;113.22: 5628–34.CrossRefGoogle Scholar
Willemze, R, Rogrigues, CA, Labopin, M, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord transplantation for acute leukemia. Leukemia 2009;23.3: 492500.CrossRefGoogle ScholarPubMed
Smith, KM. Analysis of 402 cord blood units to assess factors influencing infused viable CD 34+ cell dose: the critical determinant of engraftment. Blood 2013;122.21: 296300.Google Scholar
Eapen, M, Rocha, V, Sanz, G, et al. Effect of graft source on unrelated donor hematopoietic stem-cell transplantation in adults with acute leukemia: a retrospective analysis. Lancet Oncol 2010;11.7: 653–60.CrossRefGoogle ScholarPubMed
Brunstein, CG, Gutman, JA, Weisdorf, DJ, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010;116.22: 4693–9.CrossRefGoogle ScholarPubMed
Chen, YB, Aldridge, J, Kim, HT, et al. Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biology Blood Marrow Transplant 2012;8: 805–12.Google Scholar
Brunstein, CG, Eapen, M, Ah, KW, et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 2012;119.23: 5591–98.CrossRefGoogle ScholarPubMed
Milano, F, Gooley, T, Wood, B, et al. Cord-blood transplantation in patients with minimal residual disease. New Engl J Med 2016;375(10): 444-53.
Brunstein, CG, Fuchs EJ, EJ, Carter, SJ, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011 ;118.2: 282–88.CrossRefGoogle ScholarPubMed
Bautista, G, Cabreza, JR, Regidor, C, et al. Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor. Bone Marrow Transplant 2009;43.5: 365–73.CrossRefGoogle ScholarPubMed
Liu, H, Rich, ES, Godley, L, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood 2011;118.24: 6438–45.CrossRefGoogle ScholarPubMed
Ponce, DM, Dahi, PB, Devlin, S, et al. Double-unit cord blood transplantation combined with haplo-identical CD34+ selected PBSC results in 100% CB engraftment and enhanced myeloid recovery. Blood 2013;122: 298.Google Scholar
Frassoni, F, Gualandi, F, Podesta, M, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukemia: a phase I/II study. Lancet Oncol 2008;9.9: 831–39.CrossRefGoogle ScholarPubMed
Brunstein, C, Barker, JN, Weisdorf, DJ, et al. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units. Bone Marrow Transplant 2009;43.12: 935–40.CrossRefGoogle ScholarPubMed
Delaney, C, Heimfeld, S, Brashem-Stein, C, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nature Med 2010;16.2: 232–36.CrossRefGoogle ScholarPubMed
de Lima, M, McNiece, I, Robinson, SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012;367.24: 2305–15.CrossRefGoogle ScholarPubMed
Horwitz, ME, Chao, NJ. Rizzieri, DA, et al. Umbilical cord blood expansion with nicotinamide provides long-term mulitlineage engraftment. J Clin Invest 2014;124.7: 3121–8.CrossRefGoogle ScholarPubMed
Montesinos P, P, Peled, T, Landau, E, et al. Stem-Ex (copper chelation based) ex vivo expanded cord blood umbilical cord blood stem cell transplantation (UCBT) accelerates engraftment and improves 100 day survival in myeloablated patients compared to a registry cohort undergoing double-unit UCBT: results of a multicenter study of 101 patients with hematologic malignancies. Blood 2013;122: 295 (Abstract).Google Scholar
Goessling, W, Allen, RS, Guan, X, et al. Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Stem Cell 2011;8.4: 445–58.Google ScholarPubMed
Cutler, C, Multani, P, Robbins, D, et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood 2013;122: 3074–81.CrossRefGoogle ScholarPubMed
Popat, UR, Oran B, B, Hosing, CM, et al. Ex vivo fucosylation of cord blood accelerates neutrophil and platelet engraftment. Blood 2013;122: 691–95.Google Scholar
Farag, SS, Srivastava, S, Messina-Graham, S, et al. In-vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematologic malignancies. Stem Cell Dev 2013;22: 1007–15.CrossRefGoogle Scholar
Norkin, M, Lazarus, HM, Wingard, JR. Umbilical cord blood graft enhancement strategies: has the time come to move these into the clinic? Bone Marrow Transplant 2013;48.7: 884–9.CrossRefGoogle ScholarPubMed
Sauter, C, Abboud, M, Jia, X, et al. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. Biol Blood Marrow Transplant 2011;17.10: 112.CrossRefGoogle ScholarPubMed
Hanley, P P, Cruz, CR, Savoldo, B, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009;114.9: 1958–67.CrossRefGoogle Scholar
Brunstein, CG, Miller, J, Cao, Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011;117.3: 1061–70.CrossRefGoogle Scholar
Ballen, KK, Klein, JP, Pedersen, TL, et al. Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2012;18.6: 903–12.CrossRefGoogle Scholar
Ballen, KK, Joffe, S, Brazauskas, R, et al. Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: comparison among alternative graft sources. Biol Blood Marrow Transplant 2014;20.11:1819–27.CrossRefGoogle ScholarPubMed
Deuse, T, Stubbendorff, M. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant 2011;20.5: 655–67.CrossRefGoogle ScholarPubMed
Cui, X, Choppe, M, Zacharek, A, et al. Combination treatment of stroke with subtherapeutic doses of Simvastatin and human umbilical cord blood cells enhances vascular remodeling and improves functional outcomes. Neuroscience 2012;227: 223–31.CrossRefGoogle Scholar
Cotten, CM, Murtha, AP, Goldberg, RN, et al. Feasibility of autologous cord blood cells for infants wtih hypoxic-ischemic encephalopathy. J Pediatr 2014;164: 973–9.CrossRefGoogle Scholar
Barker, JN, Byam, C, Scaradavou, A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood 2011;117.8: 2332–9.CrossRefGoogle ScholarPubMed
Ponce, DM, Zheng, J, Gonzales, AM, et al. Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011;17.9: 1316–26.CrossRefGoogle ScholarPubMed
Marks, DI, Woo, KA, Zhong, X, et al. Unrelated umbilical cord blood transplantation for adult acute lymphoid leukemia in first or second complete remission. Hematologica. 2014;99.2: 322–8.CrossRefGoogle ScholarPubMed
Sun, J, Allison, J, McLaughlin, C, et al. Differences in quality between privately and publicly banked umbilical cord blood units: a pilot study of autologous cord blood infusion in children with acquired neurologic disorders. Transfusion 2010;50.9: 1980–7.CrossRefGoogle ScholarPubMed
Jeevanantham, V, Butler, M, Saad, A, et al. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation 2012;126.5: 551–68.CrossRefGoogle ScholarPubMed
Haller, MJ, Wasserfall, CH, Hulme, MA, et al. Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes. Biol Blood Marrow Transplant 2013;19.7: 1126–9.CrossRefGoogle ScholarPubMed

References

Lee, SJ, Klein, J, Haagenson, M, Baxter-Lowe, LA, Confer, DL, Eapen, M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007;110(13):4576–83.CrossRefGoogle ScholarPubMed
Woolfrey, A, Klein, JP, Haagenson, M, Spellman, S, Petersdorf, E, Oudshoorn, M, et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2011;17(6):885–92.CrossRefGoogle ScholarPubMed
Gragert, L, Eapen, M, Williams, E, Freeman, J, Spellman, S, Baitty, R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 2014;371(4):339–48.CrossRefGoogle ScholarPubMed
Bashey, A, Zhang, X, Sizemore, CA, Manion, K, Brown, S, Holland, HK, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-match related and unrelated donor transplantation. J Clin Oncol 2013;31(10):1310–6.CrossRefGoogle Scholar
Brunstein, CG, Eapen, M, Ahn, KW, Appelbaum, FR, Ballen, KK, Champlin, RE, et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 2012;119(23):5591–8.CrossRefGoogle ScholarPubMed
Brunstein, CG, Gutman, JA, Weisdorf, DJ, Woolfrey, AE, Defor, TE, Gooley, TA, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010;116(22):4693–9.CrossRefGoogle ScholarPubMed
Eapen, M, Rubinstein, P, Zhang, MJ, Stevens, C, Kurtzberg, J, Scaradavou, A, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007;369(9577):1947–54.CrossRefGoogle ScholarPubMed
Rocha, V, Cornish, J, Sievers, EL, Filipovich, A, Locatelli, F, Peters, C, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001;97(10):2962–71.CrossRefGoogle ScholarPubMed
Raiola, AM, Dominietto, A, di Grazia, C, Lamparelli, T, Gualandi, F, Ibatici, A, et al. Unmanipulated haploidentical transplants compared with other alternative donors and match sibling grafts. Biol Blood Marrow Transplant 2014;20(10):1573–9.CrossRefGoogle Scholar
Anasetti, C, Beatty, PG, Storb, R, Martin, PJ, Mori, M, Sanders, JE, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990;29(2):7991.CrossRefGoogle ScholarPubMed
Beatty, PG, Clift, RA, Mickelson, EM, Nisperos, BB, Flournoy, N, Martin, PJ, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985;313(13):765–71.CrossRefGoogle ScholarPubMed
Ash, RC, Horowitz, MM, Gale, RP, van Bekkum, DW, Casper, JT, Gordon-Smith, EC, et al. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant 1991;7(6):443–52.Google ScholarPubMed
Aversa, F, Terenzi, A, Tabilio, A, Falzetti, F, Carotti, A, Ballanti, S, et al. Full haplotype-mismatch hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005;23(15):3447–54.CrossRefGoogle Scholar
Martelli, MF, Di Ianni, M, Ruggeri, L, Falzetti, F, Carotti, A, Terenzi, A, et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood 2014;124(4):638–44.CrossRefGoogle ScholarPubMed
Wang, Y, Liu, DH, Liu, KY, Xu, LP, Zhang, XH, Han, W, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 2013;119(5):978–85.CrossRefGoogle Scholar
Rizzieri, DA, Koh, LP, Long, GD, Gasparetto, C, Sullivan, KM, Horwitz, M, et al. Partially match, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007;25(6):690–7.CrossRefGoogle Scholar
Kanda, J, Long, GD, Gasparetto, C, Horwitz, ME, Sullivan, KM, Chute, JP, et al. Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-match related, unrelated, or haploidentical related donors for patients with hematologic malignancies. Biol Blood Marrow Transplant 2014;20(2):257–63.CrossRefGoogle ScholarPubMed
Luznik, L, O’Donnell, PV, Symons, HJ, Chen, AR, Leffell, MS, Zahurak, M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14(6):641–50.CrossRefGoogle ScholarPubMed
O’Donnell, PV, Luznik, L, Jones, RJ, Vogelsang, GB, Leffell, MS, Phelps, M, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatch related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002;8(7):377–86.Google Scholar
Kanakry, CG, Ganguly, S, Zahurak, M, Bolanos-Meade, J, Thoburn, C, Perkins, B, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med 2013;5(211):211ra157.CrossRefGoogle ScholarPubMed
Ross, D, Jones, M, Komanduri, K, Levy, RB. Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013;19(10):1430–8.CrossRefGoogle ScholarPubMed
Kasamon, YL, Luznik, L, Leffell, MS, Kowalski, J, Tsai, HL, Bolanos-Meade, J, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010;16(4):482–9.CrossRefGoogle ScholarPubMed
Castagna, L, Crocchiolo, R, Furst, S, Bramanti, S, El-Cheikh, J, Sarina, B, et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2014;20(5):724–9.CrossRefGoogle ScholarPubMed
Raiola, AM, Dominietto, A, Ghiso, A, Di Grazia, C, Lamparelli, T, Gualandi, F, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013;19(1):117–22.CrossRefGoogle ScholarPubMed
Raj, K, Pagliuca, A, Bradstock, K, Noriega, V, Potter, V, Streetly, M, et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 2014;20(6):890–5.CrossRefGoogle ScholarPubMed
Solomon, SR, Sizemore, CA, Sanacore, M, Zhang, X, Brown, S, Holland, HK, et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012;18(12):1859–66.CrossRefGoogle ScholarPubMed
Ciurea, SO, Mulanovich, V, Saliba, RM, Bayraktar, UD, Jiang, Y, Bassett, R, et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012;18(12):1835–44.CrossRefGoogle Scholar
Wagner, JE, Eapen, M, Carter, SL, Haut, PR, Peres, E, Schultz, KR, et al. No survival advantage after double umbilical cord blood (UCB) compared to single UCB transplant in children with hematological malignancy: results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) Randomized Trial. ASH Annual Meeting Abstracts 2012;120(21):359.Google Scholar
Hwang, WY, Samuel, M, Tan, D, Koh, LP, Lim, W, Linn, YC. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biol Blood Marrow Transplant 2007;13(4):444–53.CrossRefGoogle ScholarPubMed
Eapen, M, Rocha, V, Sanz, G, Scaradavou, A, Zhang, MJ, Arcese, W, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010;11(7):653–60.Google ScholarPubMed
Rocha, V, Labopin, M, Ruggeri, A, Blaise, D, Rio, B, Cornelissen, JJ, et al. Outcomes after double cord blood transplantation compared to single cord blood transplantation in adults with acute leukemia given a reduced intensity conditioning regimen. ASH Annual Meeting Abstracts 2012;120(21):232.Google Scholar
Lindemans, CA, Chiesa, R, Amrolia, PJ, Rao, K, Nikolajeva, O, de Wildt, A, et al. Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. Blood 2014;123(1):126–32.CrossRefGoogle ScholarPubMed
Brunstein, CG, Barker, JN, Weisdorf, DJ, DeFor, TE, Miller, JS, Blazar, BR, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007;110(8):3064–70.CrossRefGoogle ScholarPubMed
Brunstein, CG, Fuchs, EJ, Carter, SL, Karanes, C, Costa, LJ, Wu, J, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatch related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011;118(2):282–8.CrossRefGoogle ScholarPubMed
Szabolcs, P, Cairo, MS. Unrelated umbilical cord blood transplantation and immune reconstitution. Semin Hematol 2010;47(1):2236.CrossRefGoogle ScholarPubMed
Jacobson, CA, Turki, AT, McDonough, SM, Stevenson, KE, Kim, HT, Kao, G, et al. Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2012;18(4):565–74.CrossRefGoogle ScholarPubMed
Ruggeri, A, Peffault de Latour, R, Carmagnat, M, Clave, E, Douay, C, Larghero, J, et al. Outcomes, infections, and immune reconstitution after double cord blood transplantation in patients with high-risk hematological diseases. Transpl Infect Dis 2011;13(5):456–65.CrossRefGoogle ScholarPubMed
Klein, AK, Patel, DD, Gooding, ME, Sempowski, GD, Chen, BJ, Liu, C, et al. T-cell recovery in adults and children following umbilical cord blood transplantation. Biol Blood Marrow Transplant 2001;7(8):454–66.CrossRefGoogle ScholarPubMed
Komanduri, KV, St John, LS, de Lima, M, McMannis, J, Rosinski, S, McNiece, I, et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 2007;110(13):4543–51.CrossRefGoogle ScholarPubMed
Kanda, J, Chiou, LW, Szabolcs, P, Sempowski, GD, Rizzieri, DA, Long, GD, et al. Immune recovery in adult patients after myeloablative dual umbilical cord blood, match sibling, and match unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012;18(11):16641676 e1.CrossRefGoogle Scholar
Dominietto, A, Raiola, AM, Bruno, B, Pende, D, Meazza, R, Gualandi, F, et al. Fast immune recovery following unmanipulated haploidentical BMT with post-transplant high-dose cyclophosphamide as GvHD prophylaxis: a comparison with siblings, unrelated donors, cord blood (EBMT abstract). Bone Marrow Transplant 2012;47:S257S258.Google Scholar
El-Cheikh, J, Roberto, C, Sabine, F, Stefania, B, Barbara, S, Angela, G, et al. Comparison of umbilical cord blood and haploidentical donor grafts in adults with high risk hematologic diseases after fludarabine cyclophosphamide and TBI 2 Gy based reduced-intensity conditioning regimen stem cell transplantation. Blood 2013;122(21):3288.Google Scholar
González-Vicent, M, Molina, B, Andión, M, Sevilla, J, Ramirez, M, Pérez, A, et al. Allogeneic hematopoietic transplantation using haploidentical donor vs. unrelated cord blood donor in pediatric patients: a single-center retrospective study. Euro J Haematol 2011;87(1):4653.CrossRefGoogle ScholarPubMed
Mo, XD, Zhao, XY, Liu, DH, Chen, YH, Xu, LP, Zhang, XH, et al. Umbilical cord blood transplantation and unmanipulated haploidentical hematopoietic SCT for pediatric hematologic malignancies. Bone Marrow Transplant 2014;49(8):1070–5.CrossRefGoogle Scholar
Huang, XJ, Liu, DH, Liu, KY, Xu, LP, Chen, H, Han, W. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatch/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007;92(3):414–7.CrossRefGoogle Scholar
Yan, CH, Liu, DH, Xu, LP, Liu, KY, Zhao, T, Wang, Y, et al. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors. Clin Transplant 2012;26(6):868–76.CrossRefGoogle ScholarPubMed
Zeidan, AM, Forde, PM, Symons, H, Chen, A, Smith, BD, Pratz, K, et al. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2014;20(3):314–8.CrossRefGoogle ScholarPubMed
Roth, JA, Bensink, ME, O’Donnell, PV, Fuchs, EJ, Eapen, M, Ramsey, SD. Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer. J Comp Eff Res 2014;3(2):135–44.CrossRefGoogle ScholarPubMed